Congress could stop IRS from enforcing individual mandate

Even if Republican-led efforts to repeal and replace the Affordable Care Act fail, the party’s members of Congress have a way to stop the Internal Revenue Service from enforcing one of the law’s most unpopular provisions: the individual mandate that penalizes people who remain uninsured.

Both the Senate and House versions of ACA repeal-and-replace legislation includes eliminating the individual mandate. As the New York Times reports, in case the Republican majorities can’t pass those bills, a provision restricting IRS enforcement of the mandate has been included in an appropriations bill for the next federal fiscal year, which begins Oct. 1.

“While Congress works to pass President Trump’s healthcare plan, stopping the IRS from implementing the harmful individual mandate helps provide relief for the families suffering under Obamacare,” said Garrett Hawkins, spokesman for Georgia Republican Rep. Tom Graves, chairman of the House Subcommittee on Financial Services and General Government, which has already approved the appropriations bill.

A de facto repeal of the mandate would have a major impact on premiums, causing them to rise in the short term. Uncertainty around its enforcement under the Trump administration has been cited by insurers requesting double-digit rate increases for 2018.

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.